AngII (angiotensin II) and its G-protein-coupled AT 1 receptor play critical roles in mediating cardiovascular diseases such as hypertension, atherosclerosis and restenosis after vascular injury. It is widely believed that AngII promotes these diseases by inducing vascular remodelling that involves hypertrophy, hyperplasia and migration of VSMCs (vascular smooth muscle cells). We have shown that transactivation of an ErbB family receptor, EGFR (epidermal growth factor receptor; ErbB1), is essential for VSMC hypertrophy and migration induced by AngII. However, the precise signal transduction mechanism by which AngII transactivates EGFR/ErbB1 and whether other ErbBs are also required for AngII function remains unclear. Recent studies suggest an involvement of a metalloprotease-dependent ErbB family ligand production in the transactivation. Here, we will discuss the roles and mechanisms of AngII/AT 1 receptor in promoting ErbB receptors transactivation in VSMCs. Further elucidation of this ErbB activation machinery not only will give us a better understanding of the critical molecular mechanism underlying vascular remodelling stimulated by AngII, but will also contribute to development of novel treatment strategies for cardiovascular diseases.
tion through tyrosine kinase activation, p42/44 mitogenactivated protein kinase/ERK (extracellular-signal-regulated kinase) activation, and proto-oncogene (c-fos and c-jun) induction in VSMCs [4] [5] [6] . By activating these signal transduction pathways, the AT 1 receptor is believed to induce both growth and migration of VSMCs that are critically involved in vascular remodelling processes leading to cardiovascular diseases [4] [5] [6] . However, the detailed molecular mechanisms by which the AT 1 receptor induces these processes remain undefined.
AngII induces EGFR (epidermal growth factor receptor) transactivation
The above-mentioned protein tyrosine phosphorylation, together with rapid induction of growth-promoting signal transduction induced by the AT 1 receptor, strongly suggest signal cross-talk between the AT 1 receptor and a tyrosine kinase that is typically activated by growth factors such as PDGF (platelet-derived growth factor) and EGF (epidermal growth factor). In fact, AngII has been shown to activate several tyrosine kinases in VSMCs through the AT 1 receptor which include JAK2 (Janus kinase) [7] , PYK2 (proline-rich tyrosine kinase 2) [8, 9] , Src [10] and the PDGF receptor [11] . We have shown that a tyrosine kinase that exists downstream of phospholipase C/Ca 2+ mediates ERK1/2 activation by AngII in VSMCs [12] . Subsequently, we identified the tyrosine kinase as the EGFR (ErbB1) [13] . Similar to EGF stimulation, AngII rapidly trans-activates the EGFR leading to the Ras/ERK cascade activation. We have further demonstrated that EGFR transactivation is also required for activation of Akt/protein kinase B, p70 S6 kinase and p38 mitogen-activated protein kinase, induction of c-Fos, and subsequent growth and migration of VSMCs [6, [14] [15] [16] [17] . In addition, we have shown that several factors that are considered to be involved in vascular diseases, including endothelin-1, ROS and mechanical stress, activate ERK in VSMCs through EGFR transactivation [18] [19] [20] . Other groups have shown transactivation of the EGFR by thrombin and oxidized low-density lipoprotein in VSMCs [21, 22] . By contrast, the functional significance of PDGF receptor or insulin-like growth factor I receptor transactivation has not yet been demonstrated [23] . These data strongly implicate EGFR/ErbB1 transactivation as a point of signalling convergence by which several cardiovascular risk factors promote cardiovascular remodelling (Figure 1 ).
Possible components of EGFR transactivation
Transactivation of EGFR by some GPCR agonists was originally reported in 1996 [24] and is now recognized for a wide variety of GPCRs as an important mechanism for signalling cross-talk that is essential to mediate critical GPCR functions [25, 26] . Thus the mechanism of EGFR transactivation and its pathophysiological significance are currently major topics of signal transduction research. Recently, many interesting and attractive findings have accumulated regarding possible components involved in EGFR transactivation. First, EGFR transactivation by GPCRs appears to require a second messenger directly and/or signal transduction pathways operated by second messengers, such as elevation of intracellular Ca 2+ [13, 27] , activation of PKC [28] and generation of ROS [20, 29, 30] . Secondly, cytosolic nonreceptor tyrosine kinase such as Src or PYK2 may be involved in the EGFR transactivation [31, 32] . Thirdly, an attractive mechanism for EGFR transactivation by a GPCR was proposed recently involving a metalloprotease-dependent EGFR/ErbB ligand production from its membrane-bound pro-form [16, 33] . These data suggest the possibility of an efficient signalling relay of the transactivation machinery involving a second messenger, tyrosine kinase, and metalloprotease ( Figure 2 ).
G-protein-independent EGFR transactivation by AngII in COS7 cells
In some AT 1 receptor mutants lacking G-protein coupling, AngII has been shown to activate cytosolic tyrosine kinases (c-Src and JAK2), indicating the presence of a G-protein/ second messenger-independent mechanism(s) for tyrosine kinase activation [34, 35] . In this regard, Seta and Sadoshima [36] reported that the AT 1 -Y319F mutant failed to transactivate EGFR, but was still capable of stimulating inositol trisphosphate production in COS7 cells. One possible interpretation of these results is that, as individual signalling components, G-protein and second messenger pathways activated by the AT 1 receptor may not be sufficient for EGFR transactivation. Another possibility is that the AT 1 receptor mutant may interrupt a critical step of EGFR transactivation through protein-protein interaction. Alternatively, the G-protein α subunit directly activates a Src family kinase [37] which may in turn stimulate a metalloprotease without the participation of second messengers, or heterotrimeric G-protein-independent ROS production may lead to the EGFR transactivation.
Possible role of ADAM (a disintegrin and metalloprotease) in mediating EGFR transactivation by AngII
Although the identity of metalloprotease(s) commonly responsible for GPCR-induced EGFR transactivation has not yet been established, both MMPs (matrix metalloproteases) and ADAM family metalloproteases are implicated in the ectodomain shedding of pro-ErbB ligands stimulated by various reagents [38] . The ADAM family has been shown to mediate extracellular cleavage of several EGFR/ErbB ligand precursors [38] [39] [40] . In addition, MMP-3 and MMP-7 have been shown to cleave and produce a mature active form of HB (heparin-binding)-EGF in vitro [38] . However, ADAMs are much better candidates for mediating GPCR-induced shedding of ErbB ligands because they are transmembrane proteins and thus are more likely to be regulated in an 'inside-outside' manner to cleave membrane-anchored growth-factor precursors. By contrast, MMPs usually act as a secreted proteases and it is therefore harder to envision how intracellular signalling from GPCRs could regulate their metalloprotease activity in the extracellular space. The intracellular domains of many ADAMs have SH3 (Src homology 3)-binding sites for signalling protein interaction and several sites for phosphorylation by serine/threonine and tyrosine kinases [40] . Several papers demonstrated inducible protein interaction with ADAM, which may modulate ADAM activity [40] . Three recent studies support a role for ADAM in mediating EGFR transactivation by GPCR agonists. Transfection of a metalloprotease-domaindeleted ADAM12 inhibited phenylephrine-induced HB-EGF shedding in cardiac myocytes and HT1080 cells, whereas it was enhanced by wild-type ADAM12 transfection [41] . By contrast, bombesin-induced HB-EGF shedding and EGFR transactivation were inhibited by expression of protease-domain-deleted ADAM10, but were enhanced by wild-type ADAM10 expression [42] . Also, antisense oligonucleotides towards ADAM10 inhibited EGFR transactivation by platelet-activating factor in NCIH292 cells [43] .
Mechanism of ADAM activation by GPCRs
The cytoplasmic tails of ADAM families are highly variable, containing specialized motifs that have been postulated to be involved in the inside-out regulation of cell signalling and activation selectivity [40] . The most common motifs are PXXP binding sites for SH3 domain-containing proteins. Several ADAMs have potential phosphorylation sites for tyrosine and/or serine/threonine kinases. The resulting phosphotyrosine residues could also provide binding sites for SH2-containing proteins. In this regard, cytosolic Src family kinases (Src, Yes, Fyn, Lck and Hck) and Abl have been shown to associate with ADAM through their SH3 sites [40] . However, whether these associations lead to activation of ADAMs remains unknown. In addition, PKC-δ is known to associate with and phosphorylate ADAM9, which is implicated in HB-EGF shedding in response to PMA [44] . Several tyrosine kinases, including c-Src, have been shown to mediate many of the AngII downstream signal transductions and functions in VSMCs [5] . Together, it is highly likely that interaction of ADAM C-terminal tail with a tyrosine kinase together with a tyrosine-phosphorylation event is involved in activation of ADAM, thus mediating EGFR transactivation by GPCRs. However, whether these ADAMs are involved in AngII-induced production of ErbB ligands, and whether GPCR-derived second messenger(s) activate them through the above-mentioned mechanism, remain unanswered. We and others have shown that the EGFR transactivation by AngII involves elevation of intracellular Ca 2+ and/or ROS in VSMCs [13, 20, 30] . We have further shown that the EGFR transactivation involves metalloprotease-dependent HB-EGF production in VSMCs [16] . However, there is a huge void in our knowledge regarding how these second messenger(s) are linked to metalloprotease activation, the character and identity of the metalloprotease, as well as the pathophysiological relevance of the metalloprotease in mediating vascular remodelling. Also, it is quite possible that an ErbB ligand other than HB-EGF is produced by a metalloprotease in response to AngII which leads to activation of ErbB-Rs (ErbB receptors) as described below.
ErbB-Rs and their ligands mediate vascular remodelling
The EGFR/ErbB family is composed of four receptor tyrosine kinases, ErbB1/EGFR, ErbB2/Neu, ErbB3 and ErbB4, each of which consists of a glycosylated ligandbinding domain, a single transmembrane domain and a cytoplasmic tyrosine kinase domain [45] . Eleven different ligands have been identified for this receptor family. EGF, transforming growth factor α, amphiregulin, HB-EGF, betacellulin, epiregulin and epigen, encoded by seven separate genes, bind to and activate EGFR/ErbB1. Betacellulin and in some cases HB-EGF activate ErbB4 in addition to ErbB1. Neuregulins, encoded by four different genes named NRG1, NRG2, NRG3 and NRG4, are ligands for ErbB3 and ErbB4. As yet, no ligand has been identified for ErbB2. Following the formation of ligand-receptor complexes, receptor dimerization occurs and signalling is initiated. Whether receptor homodimers or heterodimers are formed depends on the relative abundance of receptors and other factors that are not well understood. Most frequently, ErbB1, ErbB3 and ErbB4 form heterodimers with ErbB2. These heterodimers are considered to enhance or diversify downstream signal transduction pathways [45] [46] [47] . Many studies uncovering ErbB family functions with regard to embryonic as well as cancer development have been reported [45, 48] . However, only ErbB1/EGFR has been studied in VSMCs [49] , and no information is currently available as to whether other ErbB-Rs are involved in vascular remodelling, with exception of the presence of ErbB2 in VSMCs [50] . Importantly, all ErbB ligands are synthesized as transmembrane precursors that are proteolytically cleaved to release biologically active soluble growth factors, which act in an autocrine and/or paracrine manner [47] . Among the ErbB ligands, HB-EGF is the one ligand most implicated in vascular diseases. HB-EGF can stimulate growth and migration of VSMCs. It is expressed in vascular lesions such as in atherosclerosis and restenosis following angioplasty [51] . However, there is little known about other ErbB ligands with regard to vascular diseases. Betacellulin was shown to be a potent mitogen for VSMCs and one recent publication showed expression of betacellulin precursors in intimal and medial VSMCs in the early stage of human atherosclerotic lesions [52] . Another report showed that AngII induced epiregulin mRNA and stimulated epiregulin production in VSMCs [53] . Quite recently, expression of amphiregulin mRNA in VSMCs was reported [54] . Taken together, these data suggest the novel concept that in addition to HB-EGF and EGFR/ErbB1, distinct combinations of ErbB ligandreceptor complexes are activated by ADAM-dependent shedding of ErbB ligands, leading to unique arrays of downstream signal transduction pathways that are required for coordinate steps to induce vascular remodelling (Figure 3) .
Importance of ErbB transactivation in and beyond cardiovascular diseases
Currently, cardiovascular disease is the primary killer in the U.S.A. As described above, it is suggested that second messenger-sensitive metalloprotease activation and subsequent shedding of ErbB ligand(s) play critical roles in ErbB transactivation and resultant vascular remodelling.
Further elucidation of these mechanisms is potentially important because of the following. (i) It will uncover a previously missing signalling link from AngII and other risk factors to the EGFR/ErbB-Rs that could provide a better understanding of the molecular mechanism of cardiovascular remodelling. (ii) Identification of critical steps and components of ErbB-R transactivation are expected to provide new and alternative therapeutic targets, which will contribute to the treatment and/or prevention of cardiovascular diseases. (iii) The mechanism of ErbB-R transactivation by a GPCR such as the AT 1 receptor could be applied to other physiological as well as pathophysiological conditions where cross-talk between GPCRs and tyrosine kinases are critically involved, such as in tissue development, several cancers and inflammatory diseases.
In conclusion, further studies focusing on the mechanism of ErbB transactivation will contribute to our understanding of clinically important molecular biological problems in and beyond cardiovascular disease.
